Mirati Therapeutics Reports Third Quarter 2023 Financial Res

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter...

Related Keywords

Bristol , City Of , United Kingdom , Charles Baum , Myers Squibb , Committee For Medicinal Products Human Use , Twitter , Mirati Therapeutics Inc , Linkedin , National Comprehensive Cancer Network , Zai Lab , European Medicine Agency , European Society Of Medical Oncology Congress , Prnewswire Mirati Therapeutics Inc , Bristol Myers Squibb , Exchange Commission , Healthcare Products Regulatory Agency , Nasdaq , Mirati Therapeutic Inc , Facebook , Bristol Myers Squibb Company , Securities Exchange , Mirati Therapeutics , United Kingdom Medicines , View Release , European Society , Medical Oncology Congress , Lung Cancer , Rectal Cancer , Medicinal Products , Human Use , Conditional Marketing Authorisation Application , Contingent Value Right , Securities Act , Securities Exchange Act , Mirati Therapeutic , Annual Report , Initial Statements , Beneficial Ownership , Nc ,